Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
GlobeNewswire
· *$126.3 Million In Total Gross Proceeds from Warrant Distribution.
*
· *Over 1,900 Patients with Alzheimer’s..
· *$126.3 Million In Total Gross Proceeds from Warrant Distribution.
*
· *Over 1,900 Patients with Alzheimer’s..
*LONDON, UK / ACCESSWIRE / April 9, 2024 /* Genflow Biosciences PLC (LSE:GENF)(OTCQB:GENFF)
TR-1: Standard form for..
Not for publication, release, or distribution directly or indirectly in the United States, Canada, Australia or Japan.
This..